EUCTR2016-000616-15-PL进行中（未招募）1 期
An Open Label Evaluation of the Adrenal Suppression Potential and Trough Plasma Concentrations of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Every 12 Hours for Two Weeks in Subjects 9 to <12 Years of Age with Acne Vulgaris
Cassiopea S.P.A.0 个研究点目标入组 24 人开始时间: 2016年4月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject is male or female, 9 to <12 years of age at the time of consent/assent.
- •2. Subject must provide written informed assent and be accompanied by the parent or legal guardian at the time of assent/consent signing. The parent or legal guardian must provide written informed consent for the subject.
- •3. Females of childbearing potential1 must be using highly effective birth control methods2,3 with a negative urine pregnancy test (UPT) at the Screening and Baseline Visits.
- •4. Subject has moderate to severe facial acne vulgaris (Grade 3 or 4) as determined by the Investigator’s Global Assessment (IGA) [0 (clear) to 4 (severe) scale] and obvious acne on the trunk (i.e., shoulders, upper chest, and/or back) at the Screening Visit.
- •5. Subject has facial acne vulgaris with a minimum of 15 inflammatory lesions (papules, pustules, and nodules/cysts) and a minimum of 15 non-inflammatory lesions (open and closed comedones) at the Screening Visit.
- •6. Subject must be in general good health in the opinion of the investigator, with normal renal function as defined per protocol4 and no clinically relevant abnormalities present at the screening physical examination, in the subject’s medical history, or from safety laboratory tests (hematology, serum chemistry, and urinalysis).
- •7. Subject has normal adrenal function measured with a Cosyntropin Stimulation Test (CST) at Screening, defined as a normal pre-stimulation cortisol level and a 30-minute post-stimulation cortisol level of >18 µg/dL.
- •8. Subject and parent/guardian are able to communicate with the staff and are willing to comply with study instructions, reside at and/or return to the clinic for required visits.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 24
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subject is pregnant, lactating, or is planning to become pregnant during the study.
- •2. Subject has a Body Mass Index (BMI) for age percentile >95% .
- •3. Except for the use of contraceptives, subject reported use of any prescription drug or herbal product within two (2) weeks of Visit 2 (Baseline), any non-prescription drug or vitamin or mineral supplements within one (1) week of Visit 2 (Baseline); any known enzyme-inducer,enzyme-inhibitor, or reported chronic exposure to enzyme-inducers such as paint solvents or pesticides within 30 days of Visit 2 (Baseline).
- •4. Subject has used topical anti-acne medications containing retinoids such as tazarotene, adapalene, or tretinoin within four (4) weeks of Visit 2 (Baseline).
- •5. Subject has used the following systemic anti-acne medications: antibiotics within two (2) weeks of Visit 2 (Baseline), spironolactone within four (4) weeks of Visit 2 (Baseline), or retinoid therapy within three (3) months of Visit 2 (Baseline).
- •6. Subject has used topical corticosteroids (including inhaled and intranasal corticosteroids) within two (2) weeks of the CST at Visit 1 (Screening) and/or between Visit 1 (Screening) CST and Visit 2 (Baseline).
- •7. Subject has used systemic corticosteroids (including intramuscular and intralesional injections) within four (4) weeks of the CST at Visit 1 (Screening) and/or between the Visit 1 (Screening) CST and Visit 2 (Baseline).
- •8. Subject has used light treatments, microdermabrasion or chemical peels to the face, chest, and/or back within eight (8) weeks of Visit 2 (Baseline).
- •9. Subject has any skin or medical condition, including facial hair that could interfere with the evaluation of the test article or requires the use of interfering topical or systemic therapy.
- •10. Subject has any condition which, in the investigator’s opinion, would make it unsafe for the subject to participate in this research study.
- •11. Subject has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the study.
- •12. Subject cannot avoid any type of strenuous exercise (swimming, running, team sports, etc.) or the use of hot tubs/saunas from Visit 2 (Baseline) to the end of the study (Visit 4).
- •13. Subject has any clinically significant medical abnormality or chronic disease of the cardiovascular, gastrointestinal, respiratory, hepatic, or renal systems. This includes conditions (e.g., gastrointestinal surgery) that may interfere with metabolism or excretion.
- •14. Subject has a history of alcohol and/or drug abuse in the investigator's judgment or has a positive urine drug screen result at Visit 1 (Screening).
- •15. Subject is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function.
- •16. Subject is known to be hypersensitive to the test article or any components in the test article (see Section 6.1).
- •17. Subject has received an investigational drug or been treated with an investigational device within 30 days prior to Visit 2 (Baseline).
- •18. Subject is currently enrolled in an investigational drug or device study.
- •19. Subject has an irregular sleep schedule (cortisol levels exhibit physiological diurnal variation) as judged by the investigator.
- •20. Subject has experienced significant blood loss, as judged by the investigator, within 60 days or has donated plasma within 72 hours prior to Visit 2 (Baseline).
- •21. Subject tests positive at screening for human immunodefic
研究者
相似试验
进行中（未招募）
1 期
The research study to find out if the study drug, halobetasol propionate foam, 0.05%, is safe to give to children and teenagers who have plaque psoriasis.Plaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2018-003845-40-PLMayne Pharma LLC25
终止
4 期
Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%Plaque PsoriasisNCT03212963Sun Pharmaceutical Industries Limited16
已完成
2 期
An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne VulgarisAcne VulgarisNCT01831960Intrepid Therapeutics, Inc.42
已完成
2 期
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne VulgarisAcne VulgarisNCT02720627Cassiopea SpA27
已完成
2 期
Pharmacokinetics of 122-0551 and Its Effects on Adrenal SuppressionPlaque PsoriasisNCT01698333Therapeutics, Inc.25